Pneumagen
Signal active
Organization
Contact Information
Overview
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
About
Industries
Biotechnology, Health Care, Wellness
Founded
2016
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
Pneumagen headquartered in Europe, operates in the Biotechnology, Health Care, Wellness sector. The company focuses on Biotechnology and has secured $1.1B in funding across 48 round(s). With a team of 11-50 employees, Pneumagen is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Pneumagen, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
3
Lead Investors
0
Total Funding Amount
$23.5M
Details
0
Pneumagen has raised a total of $23.5M in funding over 0 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|
Investors
Pneumagen is funded by 26 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Esperante Ventures | - | FUNDING ROUND - Esperante Ventures | 10.0M |
| Mark Bamforth | - | FUNDING ROUND - Mark Bamforth | 10.0M |
| Pneumagen | - | FUNDING ROUND - Pneumagen | 10.0M |
| Thairm Bio | - | FUNDING ROUND - Thairm Bio | 10.0M |
Recent Activity
There is no recent news or activity for this profile.